Study of Omalizumab in Moderate to Severe Bronchial Asthma
- Sponsor
- Novartis
- Study ID
- NCT00232050
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omalizumab — DRUG
Study Details
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
Key Dates
- Start date
- Oct 31, 2002
- Status verified
- Oct 2011
- Primary completion
- May 31, 2005
- Completion
- May 31, 2005
Study Design
- Enrollment
- 327 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Morning peak expiratory flow (PEF) at baseline and end of treatment.
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent AsthmaRecruiting · Gelb, Arthur F., M.D. · Lakewood, California
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway InflammationPHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts